Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees Celebrex Script Growth After Bextra Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.

You may also be interested in...



Celebrex On The “Rebound,” Pfizer Says

Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19

Celebrex On The “Rebound,” Pfizer Says

Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19

Silver Lining For Pfizer? Celebrex Well-Positioned In NSAID Class

The boxed warning for Pfizer's Celebrex will differ only slightly from labeling for other prescription NSAIDs, FDA says. All products will bear new language addressing increased cardiovascular and gastrointestinal risks. The agency appears open to renewed direct-to-consumer advertising for Celebrex.

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel